Therefore, Du et al. [75] have recently proposed DPP-4 inhibition as a potential therapeutic strategy aimed to alleviate the cardiovascular injury (including arrhythmia, acute coronary syndrome and heart failure) caused either directly by SARS-CoV-2 or indirectly by the COVID-19-induced cytokine storm. Here, DPP4 is linked to COVID-19.